- •Brivaracetam (BRV) is an option for severe pediatric drug-resistant epilepsy.
- •Epilepsy onset >12 months is associated with a better prognosis after BRV.
- •Greater epilepsy duration and seizure frequency associate with a worse prognosis.
- •Discontinuation of BRV may be due to lack of efficacy, in severe pediatric epilepsy.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Seizure - European Journal of Epilepsy
- Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: an up to 11-year, open-label, follow-up trial.Epilepsia. 2020; 61 (Apr): 636-646https://doi.org/10.1111/epi.16484
- Potential role of brivaracetam in pediatric epilepsy.Acta Neurol Scand. 2021; 143 (Jan): 19-26https://doi.org/10.1111/ane.13347
- Stereochemistry of the Brivaracetam Diastereoisomers.Chirality. 2016; 28 (Mar): 215-225https://doi.org/10.1002/chir.22558
- New developments in the management of partial-onset epilepsy: role of brivaracetam.Drug Des Dev Ther. 2017;
- Anti-convulsive and antiepileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.Br J Pharmacol. 2008; 154: 1662-1671
- Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.Epilepsia. 2016; 57: 201-209
- A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures.Epilepsia. 2015; 56 (Dec): 1890-1898https://doi.org/10.1111/epi.13212
- Therapeutic drug monitoring of newer antiepileptic drugs: a randomized trial for dosage adjustment.Ann Neurol. 2020; 87 (Jan): 22-29https://doi.org/10.1002/ana.25641
- Randomized open-label trial of intravenous brivaracetam versus lorazepam for acute treatment of increased seizure activity.Epilepsy Behav. 2020; 109https://doi.org/10.1016/j.yebeh.2020.107127
- Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial.Neurology. 2010; 75 (10): 519-525https://doi.org/10.1212/WNL.0b013e3181ec7f7f
- Brivaracetam retention rate and seizure outcomes in patients with drug-resistant focal epilepsy included in the medical need program in Belgium: a real-world, multicenter.Chart Rev Drugs Real World Outcomes. 2021; 8 (Sepdoi:10 1007 40801-021-00246–7): 407-415
- Adjunctive Brivaracetam in Focal Epilepsy: real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).CNS Drugs. 2021; 35 (DecEpub 2021 Sep 2. Erratum in: CNS Drugs. 2021 Nov 17;: PMID: 34476770; PMCID: PMC8642333): 1289-1301https://doi.org/10.1007/s40263-021-00856-3
- Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis.Neurology. 2016; 86 (5): 1344-1352https://doi.org/10.1212/WNL.0000000000002545
- Brivaracetam add-on therapy for drug-resistant epilepsy.Cochrane Database Syst Rev. 2019; 28CD011501https://doi.org/10.1002/14651858.CD011501.pub2
- Efficacy and tolerability of intravenous brivaracetam for status epilepticus: a systematic review.J Neurol Sci. 2020; 413https://doi.org/10.1016/j.jns.2020.116799
- A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.Epilepsy Res. 2020; 166https://doi.org/10.1016/j.eplepsyres.2020.106403
- Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents.Epilepsy Behav. 2018; 89: 89-93
- Safety and tolerability of adjunctive brivaracetam in pediatric patients < 16 years with epilepsy: an open-label trial.Paediatr Drugs. 2019; 21: 291-301
- Safety and efficacy of brivaracetam in pediatric refractory epilepsy: a single-center clinical experience.J Child Neurol. 2020; 35: 102-105
- Treatment with brivaracetam in children - the experience of a pediatric epilepsy center.Epilepsy Behav. 2019; 101
- Safety and tolerability of adjunctive brivaracetam in children with focal seizures: interim analysis of pooled data from two open-label trials.Eur J Paediatr Neurol. 2020; 25: 68-76
- Clinical experience with brivaracetam in a series of 46 children.Epilepsy Behav. 2020; 107
- Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus.Epilepsia. 2018; 59: 1549-1556
- Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies [published correction appears in Epilepsia.Epilepsia. 2010; 51 (2010): 1069-1077https://doi.org/10.1111/j.1528-1167.2009.02397.x
- ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology.Epilepsia. 2017; 58: 512-521
- Operational classification of seizure types by the International League Against Epilepsy: position Paper of the ILAE Commission for Classification and Terminology.Epilepsia. 2017; 58: 512-521
F.D.A. U.S. Food and Drug Administration. CFR—Code of Federal Regulations Title 2014;21, 5:21 312 32.
- Brivaracetam in treating epileptic encephalopathy and refractory focal epilepsies in patients under 14 years of age.Iran J Child Neurol. 2020; 15https://doi.org/10.22037/ijcn.v15i4.29819
- Retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany.Front Neurol. 2018;
- Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany.Epilepsia. 2017; 58 (Jul): 1208-1216https://doi.org/10.1111/epi.13768
- Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: a longitudinal multicenter study with up to 5 years of follow-up.Epilepsia. 2021;